62 related articles for article (PubMed ID: 17114956)
21. Correlative imaging strategies implementing CT, MRI, and PET for staging of childhood Hodgkin disease.
Furth C; Denecke T; Steffen I; Ruf J; Voelker T; Misch D; Vondran F; Plotkin M; Stöver B; Henze G; Lemke AJ; Amthauer H
J Pediatr Hematol Oncol; 2006 Aug; 28(8):501-12. PubMed ID: 16912590
[TBL] [Abstract][Full Text] [Related]
22. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study.
Gallamini A; Hutchings M; Rigacci L; Specht L; Merli F; Hansen M; Patti C; Loft A; Di Raimondo F; D'Amore F; Biggi A; Vitolo U; Stelitano C; Sancetta R; Trentin L; Luminari S; Iannitto E; Viviani S; Pierri I; Levis A
J Clin Oncol; 2007 Aug; 25(24):3746-52. PubMed ID: 17646666
[TBL] [Abstract][Full Text] [Related]
23. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
Wang W; Macapinlac H; Larson SM; Yeh SD; Akhurst T; Finn RD; Rosai J; Robbins RJ
J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792
[TBL] [Abstract][Full Text] [Related]
24. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT?
Schaefer NG; Hany TF; Taverna C; Seifert B; Stumpe KD; von Schulthess GK; Goerres GW
Radiology; 2004 Sep; 232(3):823-9. PubMed ID: 15273335
[TBL] [Abstract][Full Text] [Related]
25. [Comparison of 18F-FDG coincidence SPECT imaging and computed tomography in the initial staging and therapeutic evaluation of lymphomas].
Qiao WL; Zhao JH; Wang C; He ZY; Wang TS; Xing Y
Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):536-9. PubMed ID: 18069637
[TBL] [Abstract][Full Text] [Related]
26. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A
J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046
[TBL] [Abstract][Full Text] [Related]
27. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
[TBL] [Abstract][Full Text] [Related]
28. [Comparison between conventional imaging methods and positron emission tomography in the treatment of Hodgkin's lymphoma].
Móciková H; Marková J; Bĕlohlávek O; Cáp F; Cermák F; Feltl D; Kozák T
Cas Lek Cesk; 2004; 143(7):476-9; discussion 479-80. PubMed ID: 15373291
[TBL] [Abstract][Full Text] [Related]
29. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.
Moog F; Bangerter M; Diederichs CG; Guhlmann A; Kotzerke J; Merkle E; Kolokythas O; Herrmann F; Reske SN
Radiology; 1997 Jun; 203(3):795-800. PubMed ID: 9169707
[TBL] [Abstract][Full Text] [Related]
30. Positron emission tomography scanning in the assessment of patients with lymphoma.
Foo SS; Mitchell PL; Berlangieri SU; Smith CL; Scott AM
Intern Med J; 2004 Jul; 34(7):388-97. PubMed ID: 15271172
[TBL] [Abstract][Full Text] [Related]
31. Positron emission tomography scanning in malignant melanoma.
Tyler DS; Onaitis M; Kherani A; Hata A; Nicholson E; Keogan M; Fisher S; Coleman E; Seigler HF
Cancer; 2000 Sep; 89(5):1019-25. PubMed ID: 10964332
[TBL] [Abstract][Full Text] [Related]
32. Avoiding false-positive joint scans by the use of labeled albumins.
Cohen MB; Lorber A
Arthritis Rheum; 1971; 14(1):32-3 passim. PubMed ID: 5542368
[No Abstract] [Full Text] [Related]
33. PET scans: Is it time to install these in community hospitals?
Merrell RC
Curr Surg; 2001; 58(6):525-8. PubMed ID: 16093081
[No Abstract] [Full Text] [Related]
34. Diabetes and PET Scans: Only Part of a Bigger Problem.
Khithani A
Gastrointest Cancer Res; 2009 Jul; 3(4):165-6. PubMed ID: 19742143
[No Abstract] [Full Text] [Related]
35. Drug-Related Cutaneous Adverse Events in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Literature Review.
Malato A; Rossi E; Palumbo GA; Guglielmelli P; Pugliese N
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486130
[TBL] [Abstract][Full Text] [Related]
36. A systematic review of evidence for and against routine surveillance imaging after completing treatment for childhood extracranial solid tumors.
Morgan JE; Walker R; Harden M; Phillips RS
Cancer Med; 2020 Jul; 9(14):4949-4961. PubMed ID: 32431088
[TBL] [Abstract][Full Text] [Related]
37. Pediatric Hodgkin Lymphoma: Predictive value of interim 18F-FDG PET/CT in therapy response assessment.
Ferrari C; Niccoli Asabella A; Merenda N; Altini C; Fanelli M; Muggeo P; De Leonardis F; Perillo T; Santoro N; Rubini G
Medicine (Baltimore); 2017 Feb; 96(5):e5973. PubMed ID: 28151888
[TBL] [Abstract][Full Text] [Related]
38. The clinical utility of FDG PET/CT among solid organ transplant recipients suspected of malignancy or infection.
Wareham NE; Lundgren JD; Da Cunha-Bang C; Gustafsson F; Iversen M; Johannesen HH; Kjær A; Rasmussen A; Sengeløv H; Sørensen SS; Fischer BM
Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):421-431. PubMed ID: 27838763
[TBL] [Abstract][Full Text] [Related]
39. Paediatric and adolescent Hodgkin lymphoma: information derived from diffuse organ uptake of 18 F-fluorodeoxyglucose on pre-treatment and on interim PET/CT.
Jorgov L; Montravers F; Balogova S; Ragu C; Pacquement H; Leblanc T; Abbou S; Ducou-Lepointe H; Landman-Parker J; Talbot JN
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1220-30. PubMed ID: 26660144
[TBL] [Abstract][Full Text] [Related]
40. Pediatric lymphomas and histiocytic disorders of childhood.
Allen CE; Kelly KM; Bollard CM
Pediatr Clin North Am; 2015 Feb; 62(1):139-65. PubMed ID: 25435117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
